Space Industry and Business News  
US scientists scrap major AIDS vaccine test

by Staff Writers
Washington (AFP) July 18, 2008
US scientists have scrapped plans for a large trial of a HIV vaccine due to concerns about its effectiveness, the government's medical research agency said.

The decision on the government-developed vaccine comes less than a year after a trial for a similar vaccine from the pharmaceutical company Merck failed -- marking another setback in the decades-long struggle to develop a successful vaccine to fight the scourge of AIDS.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the government's National Institutes of Health, said after consulting scientists and advocacy groups it "has determined that it will not conduct the HIV vaccine study known as PAVE 100."

"However, NIAID believes the vaccine developed by its Vaccine Research Center (VRC) is scientifically intriguing and sufficiently different from previously tested HIV vaccines to consider testing it in a smaller, more focused clinical study," the agency said in a statement issued on Thursday.

The smaller-scale study would examine if the vaccine regimen lowers the amount of HIV in the blood of vaccinated individuals, the agency said.

The trial, which was to involve 8,500 volunteers in the United States, South America, the Caribbean and Africa, had been viewed as a test of a promising vaccine that uses virus strains from around the world to prompt immunity.

The failure of Merck's vaccine influenced the decision to cancel the planned trial of the government's PAVE vaccine, US media reported on Friday.

The Merck vaccine in tests failed to prevent HIV infection or reduce the amount of HIV in the blood of patients, the government agency said.

Results also indicated that it may have even increased the risk of infection for some patients.

The official who canceled the PAVE trial, Doctor Anthony Fauci, director of the NIAID, said a large trial was not justified until fundamental questions could be answered about how the vaccine operates.

"Show me that the vaccine works by lowering the amount of HIV in the blood," Fauci was quoted as saying by the New York Times.

"Then we will move to a larger trial that will document the link with a particular immune response," he said. Until then, "doing a large trial is not justified."

The agency said it would continue to strive to find an AIDS vaccine, an effort that began more than 20 years ago.

"An HIV vaccine continues to be our best hope for ending the HIV pandemic," it said.

"NIAID is committed to supporting the basic research and vaccine discovery needed to design promising vaccine candidates and testing those candidates when appropriate."

Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola



Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News


The Way To A Virus' Heart Is Through Its Enzymes
London, UK (SPX) Jul 15, 2008
The arrival of bluetongue virus (BTV) in the UK last year posed a major threat to the economy and the increasing temperatures of our changing climate mean it is here to stay. If we are to fight this disease, which has had a major impact on farming already, we must discover how it works.







  • Google profit up 35 percent at 1.25 billion dollars
  • Microsoft posts sharp profit rise, cautious guidance
  • Google-Viacom lawsuit deal cloaks YouTube user identities
  • Brazilians first to unlock new iPhone: reports

  • AMC-21 Is Delivered To Spaceport
  • Sea Launch Delivers Echostar 11 To Orbit
  • Countdown Underway For The Launch Of The Echostar XI Satellite
  • Sea Launch Sets Sail For EchoStar XI Launch

  • China Southern Airlines managers take paycut due to oil prices
  • British PM blasts polluting 'ghost' flights
  • Air China says it is to buy 45 Boeing aircraft
  • Raytheon Leads Team To Evaluate Impact Of New Classes Of Aircraft For NASA

  • DRS Completes Testing Of PMM System
  • Boeing To Demo Net-Centric Upgrade On AWACS Aircraft
  • Satellite's Instrumentation Providing Scintillation Forecast Data
  • USAF E-8C Joint STARS Airframes Operationally Viable Through 2070

  • Advertisers' dream as Japanese display identifies customers
  • Virtual World Is Sign Of Future For Scientists And Engineers
  • Satellite Users Group Opposes UTC Request
  • EchoStar XI Satellite Deploys Solar Arrays On Schedule

  • NASA Names Strain New Goddard Space Flight Center Director
  • Raytheon IDS Names Del Checcolo Vice President, Engineering
  • John B. Higginbotham Appointed CEO Of Integral Systems
  • Sea Launch Transitions To New Leadership

  • NASA Works To Improve Short-Term Weather Forecasts
  • ESA To Consult The Science Community On Earth Explorer Selection
  • NASA's Deep Impact Films Earth As An Alien World
  • ESA Launches Program In Support Of Earth Observation Science

  • Garmin Proves Great Britain Is More Than Just Torque
  • Personal Navigation Most Popular LBS Application For Next Five Years
  • Ford's New Smart Intersection Talks To Cars To Help Reduce Fuel-Wasting Congestion
  • Real-Time Corrections Service For In-the-Field High-Accuracy Mapping

  • The content herein, unless otherwise known to be public domain, are Copyright Space.TV Corporation. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space.TV Corp on any Web page published or hosted by Space.TV Corp. Privacy Statement